linagliptin / metformin hydrochloride

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Jentadueto. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Jentadueto.

This EPAR was last updated on 07/06/2023

Authorisation details

Product details
Agency product number
Active substance
  • linagliptin
  • metformin
International non-proprietary name (INN) or common name
  • linagliptin
  • metformin hydrochloride
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Boehringer Ingelheim International GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Binger Strasse 173
D-55216 Ingelheim am Rhein

Product information

02/03/2023 Jentadueto - EMEA/H/C/002279 - WS2377

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Treatment of adult patients with type-2 diabetes mellitus:

  • Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.
  • Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
1 rating